Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants.

Giancarlo Agnelli1, Cecilia Becattini

  • 1Internal and Cardiovascular Medicine & Stroke Unit, Department of Internal Medicine, University of Perugia, Perugia, Italy. agnellig@unipg.it

Seminars in Thrombosis and Hemostasis
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bleeding risk in patients receiving concurrent treatment with direct oral anticoagulants and corticosteroids: A systematic review.

Thrombosis research·2026
Same author

Pulmonary Embolism-Attributable Mortality in Patients With Heart Failure in the United States, 2010 to 2020.

JACC. Advances·2026
Same author

Clinical phenotypes of ischaemic stroke patients and early cardiovascular complications: a latent class analysis from the Perugia Stroke Registry.

Internal and emergency medicine·2026
Same author

Pulmonary embolism epidemiology: trends, risk factors, comorbidities, and clinical implications.

European heart journal·2026
Same author

Impact of Anaemia on Management and Outcomes in Patients With Atrial Fibrillation: Insights From European and Asian Cohorts.

European journal of clinical investigation·2026
Same author

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

The New England journal of medicine·2026
Same journal

Gut Microbiome-Associated Thrombosis: Approaching Validation?

Seminars in thrombosis and hemostasis·2026
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
See all related articles

New anticoagulant drugs offer improved safety and efficacy for preventing and treating thromboembolic diseases. Molecular technology targets specific coagulation steps, addressing limitations of current therapies.

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Anticoagulant drugs are crucial for managing thromboembolic diseases.
  • Existing anticoagulants have limitations such as narrow therapeutic windows, bleeding risks, and monitoring requirements.
  • These limitations necessitate the development of novel anticoagulant therapies.

Purpose of the Study:

  • To review the development and classification of new anticoagulant drugs.
  • To highlight the advantages of novel anticoagulants over existing options.
  • To discuss the current status of new anticoagulants in clinical development.

Main Methods:

  • Review of molecular technologies used in developing new anticoagulants.
  • Classification of new anticoagulants based on their targeted step in the coagulation cascade.

Related Experiment Videos

  • Analysis of the developmental stages of various novel anticoagulant agents.

    • Main Results:

    • New anticoagulants are developed using molecular technology to target specific points in the coagulation cascade.
    • These agents are categorized into inhibitors of coagulation activation, propagation, and thrombin formation.
    • Several new anticoagulants are in various stages of development, with some already approved or in advanced clinical trials.

    Conclusions:

    • Novel anticoagulants show promise for more effective and safer treatment of thromboembolic disorders.
    • Targeted molecular approaches are advancing anticoagulant therapy.
    • The pipeline of new anticoagulants is robust, with ongoing research and clinical evaluation.